Objective. To study the clinical efficacy of modified Yiwei Shengyang decoction combined with FOLFOX4 chemotherapy regimen in the treatment of advanced gastric cancer and its effect on tumor marker levels. Methods. A total of 106 patients with advanced gastric cancer who were treated in our hospital from September 2019 to September 2021 were recruited and assigned via random number allocation to receive either FOLFOX4 chemotherapy (control group) or modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy (observation group). Outcome measures included clinical efficacy and tumor marker levels. Results. Modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy was associated with a significantly higher efficacy (86.79%, including 22 (41.51%) cases of complete response (CR), 24 (45.28%) cases of partial response (PR), 6 (11.32%) cases of stable disease (SD), and 1 (1.89%) case of progressive disease (PD)) compared to FOLFOX4 chemotherapy alone (47.16%, including 10 (18.87%) cases of CR, 15 (28.30%) cases of PR, 21 (39.62%) cases of SD, and 7 (13.21%) cases of PD) ( P < 0.05 ). There was no significant difference in the levels of CEA and CA19-9 between the two groups before treatment ( P > 0.05 ). Modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy resulted in significantly lower levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) (2.08 ± 0.47, 15.12 ± 6.74) compared to FOLFOX4 chemotherapy alone (5.46 ± 1.84, 31.82 ± 7.48) ( P < 0.05 ). Conclusion. Modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy regimen is effective in the treatment of advanced gastric cancer. It regulates the levels of various serum tumor markers in patients and controls the disease, so it is worthy of clinical application and promotion.
Objective. To assess the clinical efficacy of acupuncture on neoadjuvant chemotherapy with capecitabine plus paclitaxel and radiotherapy in progressive gastric cancer. Methods. In this randomized, double-blind, controlled clinical trial, 70 patients with advanced gastric cancer receiving radio-chemotherapy between May 2018 and June 2020 were assessed for eligibility in our institution and recruited. They were assigned via the random number table method at a ratio of 1 : 1 to receive either neoadjuvant chemotherapy with capecitabine plus paclitaxel and radiotherapy (control group) or acupuncture on neoadjuvant chemotherapy with capecitabine plus paclitaxel and radiotherapy (intervention group). The outcome measures included symptom mitigation, quality of life, and traditional Chinese medicine (TCM) symptom scores. Results. The two groups showed similar results in abdominal circumference, intraabdominal pressure, and bowel sounds before treatment ( P > 0.05 ). Acupuncture plus conventional treatment was associated with better mitigation on intraabdominal pressure (11.08 ± 1.37 vs. 12.17 ± 2.68) and bowel sounds (4 [3, 4] vs. 3 [3, 4]) versus conventional treatment alone ( P < 0.05 ). No statistically significant difference in TCM symptom scores was observed between the two groups before treatment ( P > 0.05 ). Acupuncture plus conventional treatment resulted in a lower TCM symptom score (24.63 ± 4.56 points) versus conventional treatment (31.17 ± 4.91 points) ( P < 0.05 ). The eligible patients given acupuncture showed significantly higher scores of physical function, role function, emotional function, cognitive function, and social function (81.52 ± 5.37, 88.17 ± 5.17, 85.15 ± 6.71, 78.45 ± 5.85, and 80.98 ± 7.14) versus those without acupuncture (52.98 ± 8.23, 69.87 ± 5.54, 68.24 ± 9.22, 61.34 ± 6.27, and 64.79 ± 6.89) ( P < 0.05 ). Conclusion. Acupuncture is effective in the recovery of acute toxicity after radio-chemotherapy for patients with advanced gastric cancer, which provides a certain reference for clinical treatment and is worthy of application and promotion.
Objective. The aim of this study is to evaluate the safety and tumor marker level changes of acupuncture plus chemotherapy (FOLFOX4) for advanced gastric cancer. Methods. One hundred and twenty patients with advanced gastric cancer who were treated at our hospital between May 2019 and April 2021 were recruited for prospective analysis, and all patients were allocated to the control and experimental groups in a 1 : 1 ratio using the random number table method, with 60 patients in each group. They received either chemotherapy using the FOLFOX4 regimen (control group) or the FOLFOX4 chemotherapy plus acupuncture (experimental group). Outcome measures included tumor marker levels, quality of life, and adverse events. Results. Before treatment, the two groups showed similar tumor markers levels and the MOS 36-item short-form health survey (SF-36) scores ( P > 0.05 ). FOLFOX4 chemotherapy plus acupuncture was associated with significantly lower levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and CA72-4 versus FOLFOX4 chemotherapy alone ( P < 0.05 ). The patients who were given FOLFOX4 chemotherapy plus acupuncture showed significantly increased SF-36 scores versus monotherapy of the FOLFOX4 regimen ( P < 0.05 ). The joint therapy resulted in a significantly lower incidence of adverse events versus the monotherapy ( P < 0.05 ). Conclusion. Acupuncture plus chemotherapy using the FOLFOX4 regimen can effectively regulate the serum tumor marker levels of patients with advanced gastric cancer, with a high safety profile, which provides a viable treatment alternative.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.